Combination of electromechanical mapping, PET imaging targets cardiac gene therapy

In a recent study published in Human Gene Therapy, researchers found that combining electromechanic mapping with PET imaging can improve targeting of gene therapy to hibernating ischemic heart muscles.

The study was performed in Kuopio and Turku University Hospitals and included 30 patients with coronary artery disease (CAD) and refractory angina.

The researchers used electromechanical mapping with a NOGA system that produces three-dimensional images of myocardium and converted it to a 2D bullseye map, which were then superimposed onto PET radiowater perfusion imaging maps of the myocardium. This process allowed researchers to locate the target area for intramyocardial injections in their patients.

The NOGA mapping and injection procedures took approximately four hours each. All 30 patients who underwent this procedure, it turned out to be a success.

“Patients having clear ischemic area in PET mapping and viable myocardium with reduced contractility in NOGA mapping are the optimal candidates for gene therapy. These patients showed reduced contractility and perfusion, and injections were targeted to this area. Follow-up PET imaging showed that perfusion increased in those treated areas,” wrote Professor Seppo Ylä-Herttuala of University of Eastern Finland et al.

Jodelle joined TriMed Media Group in 2016 as a senior writer, focusing on content for Radiology Business and Health Imaging. After receiving her master's from DePaul University, she worked as a news reporter and communications specialist.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.